The short answer on who qualifies

Most adults who arrive at this question have persistent hip pain, have tried physiotherapy and analgesia, and want to know whether a ChondroFiller injection is a realistic option — or whether they are already past the point where it would help. The direct answer is that three factors need to align: the cartilage damage must be focal and graded ICRS (Outerbridge) Grade III or IV, the defect must fall within a treatable size window of roughly 2–6 cm² of joint surface area, and the hip joint as a whole must retain enough structure — visible on a weight-bearing X-ray — to support the treatment.

The procedure itself is an ultrasound-guided outpatient injection, not a surgical operation. That distinction matters for many patients who want to avoid or defer an operation while still addressing the underlying damage.

Age is not a hard barrier. The treatment is most commonly offered to active adults in their 40s to mid-60s, but a 2025 case report documented complete pain relief following a ChondroFiller injection in a 32-year-old patient with a focal femoral head defect.

Pain intensity alone is not a reliable way to judge whether the criteria are met — someone with severe pain may have diffuse wear that falls outside the treatment window, while a candidate with moderate symptoms might be well matched. MRI characterisation of defect grade and size, combined with a weight-bearing X-ray of the hip joint, are both needed before any formal candidacy picture emerges.

How Tönnis grading affects your eligibility

Plain weight-bearing X-rays of the hip are graded on the Tönnis scale — a four-point classification running from Grade 0 (normal radiograph) through Grade 1 (slight joint space narrowing, mild sclerosis, small osteophytes) and Grade 2 (moderate narrowing, definite osteophytes, some loss of femoral head sphericity) to Grade 3 (severe or obliterated joint space, large subchondral cysts, significant femoral head deformity). Developed in 1972 by Professor Dietrich Tönnis in Dortmund, it remains the standard radiological staging tool for adult hip osteoarthritis.

Where this matters for ChondroFiller injection candidacy depends, critically, on which delivery route is being assessed.

For the surgical (arthroscopic) route, the published 26-patient hip cohort (JHPS, 2021) applied a strict Tönnis Grade 0–1 entry criterion. Patients with Grade 2–3 changes fared poorly in that series, with higher rates of conversion to total hip replacement. That hard ceiling is embedded in the surgical evidence base.

The injection route does not inherit the same cut-off. Because the mechanism shifts from focal structural repair — rebuilding cartilage from the base of a contained defect upward — to a top-down collagen cushion distributed across a broader surface, a degree of wider joint wear does not automatically disqualify a patient. Individuals with Tönnis Grade 2 are generally considered eligible for the injection pathway.

Tönnis Grade 3 typically excludes patients from both routes. Severe joint space obliteration and significant femoral head deformity remove the biological environment the scaffold depends on, and at that stage a hip replacement discussion becomes more appropriate.

One practical caveat: Tönnis grading has known inter-observer variability at borderline presentations, particularly where changes hover between Grade 2 and Grade 3. A grade noted on a written report carries a margin of uncertainty that direct specialist review of the imaging is better placed to resolve — which is why that distinction matters at assessment, not just on paper.

Defect size and cartilage grade: the imaging thresholds

The Outerbridge scale — often labelled ICRS grading in MRI reports — classifies cartilage damage in four steps: Grade I (surface softening or blistering, surface layer intact), Grade II (partial-thickness fissuring to less than half the cartilage depth), Grade III (fissuring beyond half depth without reaching bone), and Grade IV (full-thickness loss with subchondral bone exposed). ChondroFiller injection targets Grade III and IV lesions. Grades I and II generally retain enough structure to manage without scaffold support; diffuse Grade IV involvement across the whole joint shifts the clinical pathway towards hip replacement rather than focal repair.

The distinction between focal and diffuse damage is where this grading becomes practically important. A focal defect is bounded — surrounded by cartilage that is reasonably intact and can provide both mechanical anchoring and a biological environment for the scaffold's progenitor-cell recruitment to work. Where wear is widespread rather than contained, that anchor does not exist, and the mechanism underlying the treatment cannot function as intended.

Defect area sits within a specific working range for the injection route. The lower bound of approximately 2 cm² comes from the surgical cohort literature — the published hip series required isolated lesions larger than this — rather than from injection-specific trial data. Below that threshold, options such as microfracture or OATS may be more appropriate. The upper range for the injection pathway extends to roughly 3–6 cm² of joint surface area, though the hip-specific ceiling carries some uncertainty in the current evidence and should be treated as a clinical working estimate rather than a fixed rule. Very large or diffuse cartilage loss lies outside the scaffold's scope entirely.

This is precisely why MRI, rather than X-ray, defines this part of the assessment. Weight-bearing X-ray maps overall joint architecture and Tönnis grade but cannot measure cartilage defect geometry. Cross-sectional MRI imaging reveals defect depth, surface area, and whether the surrounding tissue is sufficiently intact — information that cannot be inferred from pain levels or from an X-ray report alone.

The typical candidate profile in plain terms

Across the clinical literature, the patient who responds best to ChondroFiller injection tends to be an active adult somewhere in their 40s to mid-60s — though age alone is not a qualifying or disqualifying factor. Younger adults with hip cartilage damage from femoroacetabular impingement (FAI) or a prior injury are equally well suited, and the treatment is not reserved for any particular decade of life.

The common thread is aetiology rather than age. Most candidates have a specific, identifiable source of focal hip cartilage damage — FAI is the most frequent cause in the hip, where bony impingement gradually strips cartilage from the acetabular rim or femoral head. Prior hip trauma, such as a dislocation or labral injury from sport, can leave a similarly bounded area of damage in an otherwise healthy joint. What typically disqualifies a patient is not being too old but rather having diffuse, generalised arthritis rather than this kind of focal wear pattern.

In symptom terms, candidates usually describe groin-centred hip pain lasting at least three to six months — often longer — that has persisted despite a genuine trial of physiotherapy, analgesia, and activity modification. That period of structured conservative management is not optional. ChondroFiller injection sits further along the pathway than first-line care; a patient who has not yet completed a course of conservative treatment would not ordinarily proceed to injection assessment.

From an imaging perspective, the profile that emerges at assessment typically shows an MRI-confirmed focal cartilage defect with reasonably intact surrounding tissue, and a weight-bearing X-ray consistent with Tönnis Grade 0 to 2 — meaning the overall joint architecture remains sufficiently preserved.

Recognising elements of this profile is a reasonable starting point, but it is not a substitute for formal assessment. Defect geometry, surrounding cartilage health, and joint-space preservation can only be established through specialist review of the actual imaging.

Factors that rule out the ChondroFiller injection

Several factors place a patient outside the scope of ChondroFiller injection, and recognising them early avoids unnecessary assessment steps.

Collagen allergy. ChondroFiller is composed of murine-derived Type I collagen — the scaffold material originates from mouse tissue. A known allergy to collagen or to murine proteins is an absolute contraindication. This is less common than other allergies but is worth disclosing at the first point of contact with any clinic.

Metabolic arthropathy. Conditions such as gout, pseudogout, or inflammatory arthritis — where crystals or immune-driven inflammation periodically attack the joint — are exclusion criteria. The distinction matters for patients reading this: these are not the same as primary hip osteoarthritis. Someone with straightforward degenerative hip wear who has no history of crystal arthropathy or inflammatory joint disease is not affected by this criterion.

Advanced joint degeneration. Tönnis Grade 3 — severe or obliterated joint space, large subchondral cysts, and significant femoral head deformity — marks the point at which the hip can no longer support focal regenerative repair. Diffuse cartilage loss spanning the whole joint surface also falls outside the scaffold's scope, regardless of any individual grading score, because the contained defect geometry the treatment depends on is absent.

Standard procedural exclusions. Active joint infection, uncontrolled systemic illness, and unresolved hip instability are reasons to defer or decline any image-guided hip injection.

On access: ChondroFiller injection is not NHS-funded and is not covered by Bupa, AXA, or most major UK private insurers. Patients in Lincolnshire and the wider region access it on a self-funded basis through specialist clinics.

Getting a formal eligibility assessment

Formal eligibility requires two imaging studies read together: an MRI to characterise defect grade and surface area, and a weight-bearing X-ray to establish Tönnis grade and confirm that overall joint space is preserved. Neither alone is sufficient — the X-ray cannot resolve cartilage depth or defect geometry, and the MRI does not capture the weight-bearing joint-space picture that Tönnis grading depends on.

The practical implication is that a written radiology report alone is an unreliable self-screening tool. Because the Tönnis scale uses descriptors such as 'slight', 'small', and 'large' without fixed measurements, the Grade 2/3 boundary is a matter of clinical judgement — one that can shift between readers. A patient interpreting their own report may draw the wrong conclusion about whether they fall inside or outside the treatable window.

The consultation brings these elements together: imaging is reviewed alongside symptom history, the extent of conservative management already completed, and, where appropriate, standardised function scoring using VAS and WOMAC to establish a baseline before any treatment decision is reached.

No GP referral is required. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. A free discovery call is available as an initial step for those unsure whether to proceed to formal consultation — to clarify what the process involves and what prior imaging or documentation to bring.